147 related articles for article (PubMed ID: 34348961)
1. Revisiting the UK Genetic Severity Score for NF2: a proposal for the addition of a functional genetic component.
Catasús N; Garcia B; Galván-Femenía I; Plana A; Negro A; Rosas I; Ros A; Amilibia E; Becerra JL; Hostalot C; Rocaribas F; Bielsa I; Lazaro Garcia C; de Cid R; Serra E; Blanco I; Castellanos E;
J Med Genet; 2022 Jul; 59(7):678-686. PubMed ID: 34348961
[TBL] [Abstract][Full Text] [Related]
2. NF2: the wizardry of merlin.
Xiao GH; Chernoff J; Testa JR
Genes Chromosomes Cancer; 2003 Dec; 38(4):389-99. PubMed ID: 14566860
[TBL] [Abstract][Full Text] [Related]
3. Clinical and molecular predictors of mortality in neurofibromatosis 2: a UK national analysis of 1192 patients.
Hexter A; Jones A; Joe H; Heap L; Smith MJ; Wallace AJ; Halliday D; Parry A; Taylor A; Raymond L; Shaw A; Afridi S; Obholzer R; Axon P; King AT; ; Friedman JM; Evans DG
J Med Genet; 2015 Oct; 52(10):699-705. PubMed ID: 26275417
[TBL] [Abstract][Full Text] [Related]
4. Genetic Severity Score predicts clinical phenotype in NF2.
Halliday D; Emmanouil B; Pretorius P; MacKeith S; Painter S; Tomkins H; Evans DG; Parry A
J Med Genet; 2017 Oct; 54(10):657-664. PubMed ID: 28848060
[TBL] [Abstract][Full Text] [Related]
5. Targeted deep sequencing of DNA from multiple tissue types improves the diagnostic rate and reveals a highly diverse phenotype of mosaic neurofibromatosis type 2.
Teranishi Y; Miyawaki S; Hongo H; Dofuku S; Okano A; Takayanagi S; Ota T; Yoshimura J; Qu W; Mitsui J; Nakatomi H; Morishita S; Tsuji S; Saito N
J Med Genet; 2021 Oct; 58(10):701-711. PubMed ID: 33067351
[TBL] [Abstract][Full Text] [Related]
6. Clinical manifestations of mutations in the neurofibromatosis type 2 gene in vestibular schwannomas (acoustic neuromas).
Welling DB
Laryngoscope; 1998 Feb; 108(2):178-89. PubMed ID: 9473065
[TBL] [Abstract][Full Text] [Related]
7. The location of constitutional neurofibromatosis 2 (NF2) splice site mutations is associated with the severity of NF2.
Baser ME; Kuramoto L; Woods R; Joe H; Friedman JM; Wallace AJ; Ramsden RT; Olschwang S; Bijlsma E; Kalamarides M; Papi L; Kato R; Carroll J; Lázaro C; Joncourt F; Parry DM; Rouleau GA; Evans DG
J Med Genet; 2005 Jul; 42(7):540-6. PubMed ID: 15994874
[TBL] [Abstract][Full Text] [Related]
8. Loss of the NF2 gene and merlin occur by the tumorlet stage of schwannoma development in neurofibromatosis 2.
Stemmer-Rachamimov AO; Ino Y; Lim ZY; Jacoby LB; MacCollin M; Gusella JF; Ramesh V; Louis DN
J Neuropathol Exp Neurol; 1998 Dec; 57(12):1164-7. PubMed ID: 9862639
[TBL] [Abstract][Full Text] [Related]
9. Prevalence and natural history of schwannomas in neurofibromatosis type 2 (NF2): the influence of pathogenic variants.
Moualed D; Wong J; Thomas O; Heal C; Saqib R; Choi C; Lloyd S; Rutherford S; Stapleton E; Hammerbeck-Ward C; Pathmanaban O; Laitt R; Smith M; Wallace A; Kellett M; Evans G; King A; Freeman S
Eur J Hum Genet; 2022 Apr; 30(4):458-464. PubMed ID: 35067678
[TBL] [Abstract][Full Text] [Related]
10. Missense mutations in the NF2 gene result in the quantitative loss of merlin protein and minimally affect protein intrinsic function.
Yang C; Asthagiri AR; Iyer RR; Lu J; Xu DS; Ksendzovsky A; Brady RO; Zhuang Z; Lonser RR
Proc Natl Acad Sci U S A; 2011 Mar; 108(12):4980-5. PubMed ID: 21383154
[TBL] [Abstract][Full Text] [Related]
11. [Neurofibromatosis type 2 (NF2)].
Araki N; Takeshima H; Saya H
Gan To Kagaku Ryoho; 1997 Sep; 24(11):1427-31. PubMed ID: 9309136
[TBL] [Abstract][Full Text] [Related]
12. Phenotypic variability associated with 14 splice-site mutations in the NF2 gene.
Kluwe L; MacCollin M; Tatagiba M; Thomas S; Hazim W; Haase W; Mautner VF
Am J Med Genet; 1998 May; 77(3):228-33. PubMed ID: 9605590
[TBL] [Abstract][Full Text] [Related]
13. Revisiting neurofibromatosis type 2 diagnostic criteria to exclude LZTR1-related schwannomatosis.
Smith MJ; Bowers NL; Bulman M; Gokhale C; Wallace AJ; King AT; Lloyd SK; Rutherford SA; Hammerbeck-Ward CL; Freeman SR; Evans DG
Neurology; 2017 Jan; 88(1):87-92. PubMed ID: 27856782
[TBL] [Abstract][Full Text] [Related]
14. Role of NF2 haploinsufficiency in NF2-associated polyneuropathy.
Hanemann CO; Diebold R; Kaufmann D
Brain Pathol; 2007 Oct; 17(4):371-6. PubMed ID: 17655741
[TBL] [Abstract][Full Text] [Related]
15. Mild familial neurofibromatosis 2 associates with expression of merlin with altered COOH-terminus.
Sainio M; Jääskeläinen J; Pihlaja H; Carpén O
Neurology; 2000 Mar; 54(5):1132-8. PubMed ID: 10720287
[TBL] [Abstract][Full Text] [Related]
16. [Phenotype-genotype study in 154 French NF2 mutation carriers].
Demange L; De Moncuit C; Thomas G; Olschwang S
Rev Neurol (Paris); 2007 Nov; 163(11):1031-8. PubMed ID: 18033041
[TBL] [Abstract][Full Text] [Related]
17. Re-evaluation of missense variant classifications in NF2.
Sadler KV; Rowlands CF; Smith PT; Hartley CL; Bowers NL; Roberts NY; Harris JL; Wallace AJ; Evans DG; Messiaen LM; Smith MJ
Hum Mutat; 2022 May; 43(5):643-654. PubMed ID: 35332608
[TBL] [Abstract][Full Text] [Related]
18. Neuropathology and molecular genetics of neurofibromatosis 2 and related tumors.
Louis DN; Ramesh V; Gusella JF
Brain Pathol; 1995 Apr; 5(2):163-72. PubMed ID: 7670657
[TBL] [Abstract][Full Text] [Related]
19. Origins of biallelic inactivation of NF2 in neurofibromatosis type 2.
Xue L; He W; Zhang Y; Wang Z; Chen H; Chen Z; Zhu W; Liu D; Jia H; Jiang Y; Wang Z; Wu H
Neuro Oncol; 2022 Jun; 24(6):903-913. PubMed ID: 34918118
[TBL] [Abstract][Full Text] [Related]
20. Diagnosis, Management, and New Therapeutic Options in Childhood Neurofibromatosis Type 2 and Related Forms.
Ruggieri M; Praticò AD; Evans DG
Semin Pediatr Neurol; 2015 Dec; 22(4):240-58. PubMed ID: 26706012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
